🇬🇧 Elrexfio in United Kingdom

NICE has issued 1 UK HTA decision

Health technology assessment

1 decision from NICE for Elrexfio in United Kingdom.

NICE TA1023 — ✓ Recommended

  • Indication assessed: treating relapsed and refractory multiple myeloma after 3 or more treatments

NICE recommended Elrexfio for treating relapsed and refractory multiple myeloma after 3 or more treatments. This decision was made based on the drug's clinical effectiveness and cost. A Patient Access Scheme and Commercial arrangement were in place.

Read official decision →

Elrexfio in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in United Kingdom

Frequently asked questions

Is Elrexfio approved in United Kingdom?

Elrexfio does not currently have UK marketing authorisation in our dataset.

Who is the marketing authorisation holder for Elrexfio in United Kingdom?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.

Has Elrexfio been assessed by UK health technology agencies?

Yes — 1 UK HTA decision on record from NICE.